New radioactive treatment for advanced bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive treatment (177Lu-FAP-2286) for people with advanced bladder cancer that has stopped responding to other therapies. It aims to see if this treatment can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has not responded to all standard treatments, and no other options are available.
- You are 18 years or older.
- Your cancer shows up strongly on a special PET scan called Ga-68-FAPI (at least half of spots are brighter than the liver).
- You are generally in good health (able to do daily activities without help).
- Your blood counts, liver, and kidney function are within a certain range (we will check these with lab tests).
- You have not had any other cancer or received radioactive therapy for cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests a new radioactive drug that targets a protein called FAP on cancer cells. It is for people with advanced stomach, pancreas, colon, bile duct, or esophageal cancers that have spread and show high FAP levels on a special scan.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a radioactive drug called Lu-177 FAP-2286 for people with cancer that started in an unknown place (CUP). It may help shrink tumors by targeting a protein found on many cancer cells.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.